Prenen, H., Fakih, M., Falchook, G., Strickler, J., Hindoyan, A., Anderson, A., … Price, T. (2022). SO-39 Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100. In Annals of Oncology (Vol. 33, pp. S373–S373). Elsevier BV. https://doi.org/10.1016/j.annonc.2022.04.437

Prenen, H., M. Fakih, G. Falchook, J. Strickler, A. Hindoyan, A. Anderson, A. Ang, T. Kurata, and T. Price. “SO-39 Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100.” In Annals of Oncology, 33:S373–S373. Elsevier BV, 2022. https://doi.org/10.1016/j.annonc.2022.04.437.

Prenen H, Fakih M, Falchook G, Strickler J, Hindoyan A, Anderson A, et al. SO-39 Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100. In: Annals of Oncology. Elsevier BV; 2022. p. S373–S373.

Prenen, H., et al. “SO-39 Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S373–S373. Crossref, doi:10.1016/j.annonc.2022.04.437.

Prenen H, Fakih M, Falchook G, Strickler J, Hindoyan A, Anderson A, Ang A, Kurata T, Price T. SO-39 Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100. Annals of Oncology. Elsevier BV; 2022. p. S373–S373.